Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review (Q34630653)

3 August 2017

1 reference

title

Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review (English)

1 reference

3 August 2017

2

Alan J Wein

1 reference

3 August 2017

Eric S Rovner

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

41

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

6-14

1 reference

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

The patient with an overactive bladder--symptoms and quality-of-life issues

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Economic costs of urinary incontinence in 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Barriers to help seeking in people with urinary symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Behavioral vs Drug Treatment for Urge Urinary Incontinence in Older Women

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Combined behavioral and drug therapy for urge incontinence in older women

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Pharmacologic options for the overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

1 reference

7 January 2021

A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Treatment of urge incontinence in Veterans Affairs medical centers

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Xerostomia and hyposalivation: causes, consequences and treatment in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Xerostomia, xerogenic medications and food avoidances in selected geriatric groups

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Medical correlates of urinary incontinence in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Medication use in residential care facilities for the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

The effect of prescribed daily dose frequency on patient medication compliance

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Participants in noncompliance research: compliant or noncompliant?

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Current status of sustained release formulations in the treatment of hypertension. An overview

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900009-4

7 January 2021

10.1016/S0302-2838(01)00009-4

Identifiers

DOI

1 reference

3 August 2017

1 reference